Benzodiazepine Receptor Quantification in vivo in Humans Using [11C]Flumazenil and PET: Application of the Steady-State Principle

Carbon-11-labeled flumazenil combined with positron emission tomography (PET) was used to measure the concentration (Bmax) of the benzodiazepine (Bz) receptor in the brain and its equilibrium dissociation constant (KD) for flumazenil in five normal subjects. The steady-state approach was used injecting the tracer as a bolus of high specific activity. In each subject two studies were carried out. The first study was performed at essentially zero receptor occupancy, the tracer alone study. The second study was performed at a steady-state receptor occupancy of about 50%, achieved by a prolonged constant infusion of nonlabeled (“cold”) flumazenil starting 2 h before the bolus tracer injection and continuing until the end of the scanning period. In this second study the free concentration of unmetabolized flumazenil in plasma water was measured in multiple blood samples. The observed tissue and plasma tracer curves, calibrated in the same units of radioactivity per millimeter, were analyzed in two ways: (a) by the noncompartmental (stochastic) approach making no assumptions regarding number of compartments in the tissue, and (b) by the single-compartment approach assuming rapid exchange (mixing) of tracer between all tissue compartments. The noncompartmental and the compartmental analyses gave essentially the same values for the distribution volume of the tracer, the parameter used for quantitation of the Bz receptor. As the compartmental approach could be applied to a shorter observation period (60 min instead of 120 min) it was preferred. The five subjects had a mean KD value of 12 nM/L of water and Bmax values of the grey matter ranging from 39 ± 11 in thalamus to 120 ± 14 nM/L of brain in occipital cortex. Most previous studies have been based on the pseudoequilibrium approach using the brain stem as a receptor-free reference region. This yields practically the same KD but lower Bmax values than the steady-state approach presented here.

[1]  M. Iyo,et al.  Quantitative in vivo analysis of benzodiazepine binding sites in the human brain using positron emission tomography , 1991, Neuropharmacology.

[2]  Bernard Bendriem,et al.  Modeling Analysis of [11C]Flumazenil Kinetics Studied by PET: Application to a Critical Study of the Equilibrium Approaches , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  Peter Herscovitch,et al.  Comparison of Bolus and Infusion Methods for Receptor Quantitation: Application to [18F]Cyclofoxy and Positron Emission Tomography , 1993, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[4]  W. Wisden,et al.  Function and pharmacology of multiple GABAA receptor subunits. , 1991, Trends in pharmacological sciences.

[5]  Karl J. Friston,et al.  Localisation in PET Images: Direct Fitting of the Intercommissural (AC—PC) Line , 1989, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  J. Baron,et al.  Regional Specific Binding of [11C]RO 15 1788 to Central Type Benzodiazepine Receptors in Human Brain: Quantitative Evaluation by PET , 1988, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[7]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  N. Lassen,et al.  Tracer kinetic methods in medical physiology , 1979 .

[9]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[10]  Christer Halldin,et al.  Saturation analysis of specific 11C Ro 15‐1788 binding to the human neocortex using positron emission tomography , 1989 .

[11]  D Comar,et al.  Synthesis of ethyl 8-fluoro-5,6-dihydro-5-[11C]methyl-6-oxo-4H-imidazo [1,5-a] [1,4]benzodiazepine-3-carboxylate (RO 15.1788-11C): a specific radioligand for the in vivo study of central benzodiazepine receptors by positron emission tomography. , 1984, The International journal of applied radiation and isotopes.

[12]  S. Woods,et al.  Receptor binding characterization of the benzodiazepine radioligand 125I-Ro16-0154: potential probe for SPECT brain imaging. , 1990, Life sciences.

[13]  M. Phelps,et al.  Effects of Temporal Sampling, Glucose Metabolic Rates, and Disruptions of the Blood—Brain Barrier on the FDG Model with and without a Vascular Compartment: Studies in Human Brain Tumors with PET , 1986, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[14]  A. Nordberg,et al.  Neuroreceptor changes in Alzheimer disease. , 1992, Cerebrovascular and brain metabolism reviews.

[15]  D E Kuhl,et al.  Differentiation of Radioligand Delivery and Binding in the Brain: Validation of a Two-Compartment Model for [11C]Flumazenil , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[16]  D. R. Turton,et al.  An automated system based on solid phase extraction and HPLC for the routine determination in plasma of unchanged carbon-11 L-deprenyl Carbon-11 diprenorphine; carbon-11 flumazenil; Carbon-11 raclopride and Carbon-11 Scherring 23390 , 1993 .

[17]  R. Frackowiak,et al.  Measurement of Cerebral Monoamine Oxidase B Activity Using L-[11C]Deprenyl and Dynamic Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[18]  M. Memo,et al.  The differences in the pharmacological profiles of various benzodiazepine recognition site ligands may be associated with GABAA receptor structural diversity. , 1990, Advances in biochemical psychopharmacology.

[19]  A. Mans,et al.  Regional Distribution and Kinetics of Three Sites on the GABAA Receptor: Lack of Effect of Portacaval Shunting , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[20]  T J Spinks,et al.  Physical performance of a positron tomograph for brain imaging with retractable septa. , 1992, Physics in medicine and biology.

[21]  N. Lassen,et al.  Neuroreceptor Quantitation in vivo by the Steady-State Principle Using Constant Infusion or Bolus Injection of Radioactive Tracers , 1992, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  J. Baron,et al.  Central benzodiazepine receptors in human brain: estimation of regional Bmax and KD values with positron emission tomography. , 1992, European journal of pharmacology.